| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3634 |
| Trial ID | NCT06097455 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | BCMA|CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ARI0003 |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | First in Human, Pilot, Open-label, Prospective, Multicentre, Non-randomised Clinical Trial to Evaluate the Safety and Efficacy of ARI0003 (CART CD19/ CD269 Cells) in Patients With Relapsed/Refractory B-cell Aggressive Lymphoma |
| Year | 2024 |
| Country | Spain |
| Company sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Other ID(s) | CARTD-BG-1|2023-5072-13-97-00 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||